Copyright
©The Author(s) 2020.
World J Gastroenterol. Sep 21, 2020; 26(35): 5314-5327
Published online Sep 21, 2020. doi: 10.3748/wjg.v26.i35.5314
Published online Sep 21, 2020. doi: 10.3748/wjg.v26.i35.5314
Clinical features | Resistance mutation (+), n = 6982 | Resistance mutation (-), n = 12458 | P value | The MHR Mutation occurrence [(+) vs (-)] |
Age in year | 44.01 ± 11.73 | 39.01 ± 13.08 | < 0.05 | |
Gender, male | 5709 (81.77%) | 9982 (80.13%) | < 0.05 | |
HBV genotype, C%/B% | 86.79/12.52 | 83.00/16.05 | < 0.05 | |
HBV DNA as log10 IU/mL | 4.62 (3.17, 6.47) | 4.24 (2.83, 6.16) | < 0.05 | |
sY100S | 20 (0.29%) | 29 (0.23%) | NS | |
sQ101H/K/R | 298 (4.27%) | 229 (1.84%) | < 0.05 | ↑ |
sM103I/T | 8 (0.11%) | 14 (0.11%) | NS | |
sL109I/P/R | 12 (0.17%) | 24 (0.19%) | NS | |
sP111L/Q/S | 10 (0.14%) | 21 (0.17%) | NS | |
sG112K/R | 4 (0.06%) | 9 (0.07%) | NS | |
sS114A/L/T | 117 (1.68%) | 137 (1.10%) | < 0.05 | ↑ |
sT115A/N | 2 (0.03%) | 8 (0.06%) | NS | |
sT116N | 6 (0.09%) | 32 (0.26%) | < 0.05 | ↑ |
sS117G/N/R | 5 (0.07%) | 19 (0.15%) | NS | |
sT118A/K/M/R/S/V | 31 (0.44%) | 32 (0.26%) | < 0.05 | ↑ |
sG119E/R/T | 6 (0.09%) | 10 (0.08%) | NS | |
sP120A/L/Q/S/T | 107 (1.53%) | 35 (0.28%) | < 0.05 | ↑ |
sC121R/S | 1 (0.01%) | 1 (0.01%) | NS | |
sK122R | 154 (2.21%) | 315 (2.53%) | NS | |
sT123A/I/N/S/V | 56 (0.80%) | 91 (0.73%) | NS | |
sC124R/Y | 4 (0.06%) | 9 (0.07%) | NS | |
sT125A/M | 8 (0.11%) | 21 (0.17%) | NS | |
sT/I126A/N/P/S | 366 (5.24%) | 534 (4.29%) | < 0.05 | ↑ |
sP127H/L/S/T | 91 (1.30%) | 165 (1.32%) | NS | |
sA128T/V | 7 (0.10%) | 15 (0.12%) | NS | |
sQ129N/H/P/R | 90 (1.29%) | 129 (1.04%) | NS | |
sG130A/K/N/R/S | 65 (0.93%) | 85 (0.68%) | NS | |
sT131A/I/K/N | 133 (1.90%) | 219 (1.76%) | NS | |
sS132F/P | 2 (0.03%) | 9 (0.07%) | NS | |
sM133I/L/T | 196 (2.81%) | 277 (2.22%) | < 0.05 | ↑ |
sF/Y134H/L/R/S/V | 65 (0.93%) | 51 (0.41%) | NS | |
sS136F/P/Y | 6 (0.09%) | 4 (0.03%) | NS | |
sC137W/Y | 9 (0.13%) | 5 (0.04%) | < 0.05 | ↑ |
sC139R/S/Y | 3 (0.04%) | 9 (0.07%) | NS | |
sT140I | 39 (0.56%) | 61 (0.49%) | NS | |
sK141E/R | 3 (0.04%) | 4 (0.03%) | NS | |
sP142L | 11 (0.16%) | 9 (0.07%) | NS | |
sD144A/E | 17 (0.24%) | 26 (0.21%) | NS | |
sG145A/R | 123 (1.76%) | 163 (1.31%) | < 0.05 | ↑ |
sC147R/Y | 0 | 0 | NS | |
sS154P | 1 (0.01%) | 2 (0.02%) | NS | |
sA159G/V | 223 (3.19%) | 319 (2.56%) | < 0.05 | ↑ |
sV168A | 143 (2.05%) | 234 (1.88%) | NS | |
Average number/patient | 0.35 | 0.27 | < 0.05 | ↑ |
Patient percentage with the MHR mutation(s) | 23.32% (1628/ 6982) | 18.51% (2306/12458) | < 0.05 | ↑ |
- Citation: Huang BX, Liu Y, Fan ZP, Si LL, Chen RJ, Wang J, Luo D, Wang FS, Xu DP, Liu XG. Investigation of immune escape-associated mutations of hepatitis B virus in patients harboring hepatitis B virus drug-resistance mutations. World J Gastroenterol 2020; 26(35): 5314-5327
- URL: https://www.wjgnet.com/1007-9327/full/v26/i35/5314.htm
- DOI: https://dx.doi.org/10.3748/wjg.v26.i35.5314